TY - JOUR
T1 - Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
AU - Yale SARS-CoV-2 Genomic Surveillance Initiative
AU - Rodino, Kyle G.
AU - Peaper, David R.
AU - Kelly, Brendan J.
AU - Bushman, Frederic
AU - Marques, Andrew
AU - Adhikari, Hriju
AU - Tu, Zheng Jin
AU - Rolon, Rebecca Marrero
AU - Westblade, Lars F.
AU - Green, Daniel A.
AU - Berry, Gregory J.
AU - Wu, Fann
AU - Annavajhala, Medini K.
AU - Uhlemann, Anne Catrin
AU - Parikh, Bijal A.
AU - McMillen, Tracy
AU - Jani, Krupa
AU - Esther Babady, N.
AU - Hahn, Anne M.
AU - Koch, Robert T.
AU - Grubaugh, Nathan D.
AU - Rhoads, Daniel D.
AU - Billig, Kendall
AU - Breban, Mallery
AU - Vogels, Chantal
AU - Pham, Kien
AU - Chen, Nicholas
AU - Chaguza, Chrispin
AU - Tikhonova, Irina
AU - Castaldi, Christopher
AU - Mane, Shrikant
AU - De Kumar, Bony
AU - Ferguson, David
AU - Kerantzas, Nicholas
AU - Landry, Marie
AU - Schulz, Wade
N1 - Funding Information:
K.G.R., B.J.K., F.B., and A.M. acknowledge funding provided by a contract award from the Centers for Disease Control and Prevention (CDC BAA 200-2021-10986 and 75D30121C11102/000HCVL1-2021-55232), by philanthropic donations to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and in part by NIH grant R61/33-HL137063 and AI140442—supplement for SARS-CoV-2. Additional assistance was provided by the Penn Center for AIDS Research (P30-AI045008) and in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00015. B.J.K. is also supported by NIH K23 AI121485. D.A.G., G.J.B., F.W., M.K.A., and A.-C.U. acknowledge in part NIH funding (U01 DA053949) and the Columbia University Biobank team. T.M., K.J., and N.E.B. acknowledge funding in part through the National Institute of Heath/National Cancer Institute Cancer Center Support (Grant P30 CA008748) and Philanthropic Funds from the Burns Family. NDG acknowledges funding provided by the Centers for Disease Control and Prevention Broad Agency Announcement (75D30120C09570).
Publisher Copyright:
Copyright © 2022 American Society for Microbiology. All Rights Reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Mutations in the genome of SARS-CoV-2 can affect the performance of molecular diagnostic assays. In some cases, such as S-gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here, we describe partial ORF1ab gene target failure (pOGTF) on the cobas SARS-CoV-2 assays, defined by a $2-thermocycle delay in detection of the ORF1ab gene compared to that of the E-gene. We demonstrate that pOGTF is 98.6% sensitive and 99.9% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may affect transmission, infectivity, and/ or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly, increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities.
AB - Mutations in the genome of SARS-CoV-2 can affect the performance of molecular diagnostic assays. In some cases, such as S-gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here, we describe partial ORF1ab gene target failure (pOGTF) on the cobas SARS-CoV-2 assays, defined by a $2-thermocycle delay in detection of the ORF1ab gene compared to that of the E-gene. We demonstrate that pOGTF is 98.6% sensitive and 99.9% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may affect transmission, infectivity, and/ or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly, increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities.
KW - ORF1ab gene
KW - RT-PCR
KW - SARS-CoV-2
KW - cycle threshold (CT) value
KW - partial ORF1ab gene target failure (pORF1ab)
KW - whole-genome sequencing (WGS)
UR - http://www.scopus.com/inward/record.url?scp=85132454509&partnerID=8YFLogxK
U2 - 10.1128/jcm.00600-22
DO - 10.1128/jcm.00600-22
M3 - Article
C2 - 35582905
AN - SCOPUS:85132454509
VL - 60
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
SN - 0095-1137
IS - 6
ER -